ALKBH5 and melanoma: Li et al.’s results suggest that m6A demethylases in tumor cells increase immunotherapy efficacy, and they found ALKBH5 to be one probable therapeutically related target for enhancing immunotherapy outcome in carcinomas (e.g., CRC and melanoma).